



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2015

Swine IFITM proteins potently inhibit influenza A virus replication

Lanz, C ; Yangüez, E ; Andenmatten, D ; Stertz, S

Abstract: Human IFITMs were identified as restriction factors of influenza A virus (IAV). Given the important role of pigs in the zoonotic cycle of IAV we cloned swine IFITMs (swIFITM) and found two IFITM1-like proteins, one homologue of IFITM2 and one of IFITM3. We show that swIFITM2 and swIFITM3 localize to endosomes and display potent antiviral activity. Knockdown of swIFITMs strongly reduced virus inhibition by interferon establishing the swIFITMs as potent restriction factors in porcine cells.

DOI: <https://doi.org/10.1128/JVI.02516-14>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-101518>

Journal Article

Accepted Version

Originally published at:

Lanz, C; Yangüez, E; Andenmatten, D; Stertz, S (2015). Swine IFITM proteins potently inhibit influenza A virus replication. *Journal of Virology*, 89(1):863-869.

DOI: <https://doi.org/10.1128/JVI.02516-14>

1 **Swine IFITM proteins potentially inhibit influenza A virus replication**

2

3 **Running title: Antiviral activity of swine IFITM proteins**

4

5 Caroline Lanz^{1,2}, Emilio Yáñez¹, Dario Andenmatten¹ and Silke Stertz^{1*}

6

7 ¹ Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland

8 ² Life Sciences Zurich Graduate School, ETH and University of Zürich, 8057 Zurich, Switzerland

9

10

11 * Corresponding author: Silke Stertz, Ph.D.

12 e-mail: stertz.silke@virology.uzh.ch

13 phone: +41 44 634 2899

14 fax: +41 44 634 4967

15

16 word counts:

17 abstract: 75 words

18 main text: 1776 words

19

20 **Abstract**

21 Human IFITMs were identified as restriction factors of influenza A virus (IAV). Given the important
 22 role of pigs in the zoonotic cycle of IAV we cloned swine IFITMs (swIFITM) and found two
 23 IFITM1-like proteins, one homologue of IFITM2 and one of IFITM3. We show that swIFITM2 and
 24 swIFITM3 localize to endosomes and display potent antiviral activity. Knockdown of swIFITMs
 25 strongly reduced virus inhibition by interferon establishing the swIFITMs as potent restriction
 26 factors in porcine cells.

27 **Main text**

28 The interferon-inducible transmembrane proteins (IFITMs) were identified as potent inhibitors of
 29 different viruses, including influenza A virus (IAV), West Nile Virus, SARS coronavirus and others
 30 (1-5). In particular, human and mouse IFITM3 have been studied regarding their antiviral potential
 31 but also the mechanism of viral restriction. *Ifitm3* knockout mice showed accelerated disease
 32 progression and higher morbidity and mortality upon IAV infection (6). Moreover, it was found that
 33 humans with a single nucleotide polymorphism in the *ifitm3* gene have a significantly higher risk
 34 for a severe course of IAV infection (6, 7). The antiviral mechanism of the IFITMs is not yet fully
 35 understood but it has become clear that viral fusion is targeted by these proteins (8-11). While we
 36 have a good understanding of the antiviral potential of human and mouse IFITMs, much less is
 37 known about the activity of IFITMs in other species. Given the important role of pigs in the
 38 zoonotic cycle of IAV we aimed to elucidate the antiviral potential of swine IFITM (swIFITM)
 39 proteins.

40 We cloned swIFITMs from cDNA obtained from interferon (IFN)-stimulated pig cells according to
 41 sequences deposited in the NCBI database. We were able to amplify the porcine homologues of
 42 human IFITM1, IFITM2 and IFITM3. For IFITM1, two porcine homologues that differ in their N-
 43 and C-termini, named swIFITM1a and 1b, were found. Swine IFITM5 could not be amplified out
 44 of cDNA and was thus synthesized. The amino acid alignment of the IFITM proteins from
 45 humans, pigs and chickens shows that the IFITMs display certain features that are conserved
 46 across all three species, such as the two transmembrane domains, the palmitoylation sites at
 47 positions 73 and 74 or the ubiquitination sites at positions 85, 90 and 106 (Fig.1A) (12-14).
 48 Moreover, swine and human IFITM2 and IFITM3 share an N-terminal extension of about 20
 49 amino acids that contains the endocytosis motif YEML, which the IFITM1 proteins of both species
 50 lack (Fig.1A) (15, 16). This alignment suggests that the swine IFITM proteins could have similar
 51 antiviral properties as their human counterparts.

52 The induction of human IFITM1-3 upon IFN stimulation or virus infection is well-established (1,
53 17). While Miller *et al.* showed that in pigs swIFITMs are induced in tracheobronchial lymph
54 nodes upon infection (18), a direct induction of swIFITMs upon IFN treatment has not been
55 established to date. We thus tested the inducibility of swIFITMs upon IFN stimulation or IAV
56 infection in porcine cell lines. We stimulated porcine NpTr, PK-15 or NSK cells with universal IFN
57 (1000 U/ml) for 24h or infected with A/WSN/33 (WSN) (MOI 0.01) for 24h or 48h (19). RT-qPCR
58 with specific primers for the individual swIFITMs (primer sequences available upon request)
59 revealed a pronounced upregulation of swIFITM1a, swIFITM1b, swIFITM2 and swIFITM3 upon
60 IFN-stimulation or infection in NSK as well as PK-15 cells (Fig.1B, C). In contrast, swIFITM
61 transcripts were induced less than 3-fold in NpTr cells (Fig.1D). Moreover, when we treated NpTr
62 cells with strong inducers of the IFN response, such as IAV lacking NS1, poly(I:C) or a
63 preparation of Sendai virus that contains large amounts of defective interfering particles, we
64 detected only low levels of swIFITM induction (Fig.1E). This was not limited to swIFITMs; also
65 swine MX1 and swine OAS, both known to be upregulated by IFN, displayed only low levels of
66 induction. This suggests that the NpTr cells are not able to mount a strong IFN response. Despite
67 these differences in the induction of the swIFITMs, all three cell lines were permissive for robust
68 replication of IAV (Fig.1F). Expression of swIFITM5 could not be detected in any of the cell lines
69 (data not shown). These results suggest that like their human counterparts, swIFITM1-3
70 constitute a first line of defence against viral infections.

71 Next, we analyzed the subcellular localization of the swIFITMs. We transiently transfected human
72 A549, swine NpTr or swine NSK cells with constructs encoding flag-tagged human or swine
73 IFITMs. IFITM proteins were stained using an antibody against the flag-tag, while late endosomes
74 were marked using an antibody recognizing lysobisphosphatidic acid (LBPA) (20). Confocal
75 microscopy revealed that the subcellular localization of porcine IFITMs is similar to their human
76 homologues, with swIFITM1a and 1b localizing predominantly to the plasma membrane while
77 swIFITM2 and 3 accumulate in late endosomes. This is illustrated by their co-localization with the

late endosomal marker LBPA in representative images (Fig.2A) and the quantification of co-localization from 8-12 cells per construct and cell line (Fig.2B). Of note, human and swine IFITM2 displayed the highest degree of co-localization with LBPA. The observed localization for the human IFITMs is in agreement with previous reports for overexpressed but also for endogenous human IFITMs validating our approach (8). Moreover, the endosomal localization of human and swine IFITM2 and 3 confirms the importance of the endocytosis motif in the N-terminus for pronounced localization to endosomes (15, 16). When we analyzed the localization of the swIFITM proteins during IAV infection we did not detect changes in their intracellular distribution compared to uninfected cells (Fig.2C).

To evaluate the antiviral potential of swIFITMs we performed an IAV reporter assay in cells transiently transfected with the different swIFITMs. The reporter plasmid encodes luciferase in complementary reverse orientation flanked by IAV non-coding regions, preceded by a human or swine pPoll promoter for use in human or porcine cells, respectively. This assay provides the advantage that only reporter activity from transfected cells is measured, enabling us to assess the impact of the different IFITM proteins on IAV in a transient transfection system. The construct for human cells has been used before (21) and, for porcine cells, we adapted a construct described previously by introducing three mutations at positions 3, 5 and 8 in the promoter region (22, 23). After transfection with the reporter plasmid plus the indicated IFITM-encoding plasmid, we infected with IAV A/WSN/33 at an MOI of 0.1 in HEK293-T and an MOI of 1 in NpTr cells and measured luciferase production 24h post infection (p.i.). We observed that swIFITMs show a dose-dependent restriction of IAV in HEK293-T cells, with swIFITM2 and 3 being the most antivirally active and their activity being comparable to huIFITM3 (Fig.3A). However, it should also be noted that swIFITM2, swIFITM3 and huIFITM3 were expressed to higher levels than the other IFITMs, which is in line with the dose-dependency of restriction. We then confirmed the antiviral activity of swIFITMs in porcine cells, with swIFITM2 showing the most potent restriction

103 of IAV (Fig.3B). These data from the transient transfection assay suggest that the swIFITM
104 proteins possess antiviral activity.

105 In order to corroborate these findings, we generated stable cell lines overexpressing the different
106 swIFITMs in the background of the porcine NpTr and NSK cells by lentiviral transduction. Cells
107 were subcloned until more than 99% of cells were positive for expression. To test the antiviral
108 activity of overexpressed swIFITMs we infected the cell lines with either the human strain
109 A/HongKong/68 (MOI 1), or the swine isolate A/swine/Zurich/25/06 (MOI 1). At 48h p.i.,
110 supernatants were harvested and viral titers determined by plaque assay. Expression of the
111 swIFITMs reduced viral titers of IAV in the NpTr cell lines, with swIFITM2 being the most potent
112 and reducing titers around 1000-fold (Fig.3C, D). It should be noted that we were not able to
113 generate stable NpTr cell lines expressing high levels of swIFITM3 and 5 (Fig.3E), which could
114 contribute to the reduced potency of swIFITM3 compared to swIFITM2. In the NSK cell lines, we
115 also observed potent inhibition of IAV replication upon expression of the different swIFITMs,
116 except for swIFITM1b (Fig.3F, G). Again, swIFITM2 displayed the most potent antiviral activity.
117 As in the NpTr cells, we were not able to generate cell lines expressing high levels of swIFITM3
118 or swIFITM5. These data suggest that high expression levels of these two swIFITM proteins are
119 not well tolerated in porcine cells. The differences in expression levels make a direct comparison
120 of the antiviral activity difficult since we observed in the transient transfection assay in 293T that
121 higher expression levels lead to better inhibition of IAV. However, when comparing swIFITM2 to
122 swIFITM1a or 1b, expression levels are similar but swIFITM2 is the most active. Moreover,
123 swIFITM3 despite being expressed at much lower levels than swIFITM1a or 1b has comparable
124 activity. We therefore suggest that swIFITM2 and swIFITM3 which localize predominantly to late
125 endosomes display the strongest antiviral potential.

126 Since the assays described above were performed with overexpressed swIFITMs, we next
127 assessed whether endogenous swIFITMs also reduce viral replication. To this aim, porcine NSK

128 cells were transfected with two different siRNAs targeting swIFITMs (siIFITM #1, siIFITM #2), a
 129 positive control siRNA against the viral nucleoprotein NP or a negative control non-targeting
 130 siRNA. At 36h post transfection, cells were either mock-treated or treated with universal type I
 131 IFN (1000 U/ml). At 12h post treatment, cells were infected with IAV A/WSN/33 (MOI 0.0001),
 132 supernatants were harvested at 24h p.i. and virus titers were determined by plaque assay. In the
 133 absence of IFN, knockdown of swIFITM had no effect on virus titers (Fig.4A grey bars). However,
 134 in IFN-treated cells, viral titers were increased by 10-fold when swIFITMs were downregulated
 135 (Fig.4A black bars). To confirm that knockdown by siRNA was successful we measured mRNA
 136 levels for the different swIFITMs and swMX1 in parallel samples and found that both siRNAs
 137 designed to target all IFN-induced swIFITMs potently downregulated their expression, whereas
 138 swMX1 as a control IFN-stimulated gene was not affected (Fig.4B, C). Knockdown of swIFITMs
 139 by the two different siRNAs was further confirmed at the level of protein. Since detection of
 140 endogenous porcine swIFITM proteins was unsuccessful using available antibodies for human
 141 IFITMs we tested the siRNAs in the NSK cell lines overexpressing swIFITMs and confirmed
 142 knockdown (Fig.4D). Downregulation of viral NP levels by the NP-specific siRNA was also
 143 confirmed by western blot (Fig.4E). These data show that swIFITMs constitute an important part
 144 of the IFN response against IAV in porcine cells and confirm our results obtained with
 145 overexpression of swIFITMs.

146 In summary, we show that swIFITM1-3 are upregulated by type I IFN and IAV infection in porcine
 147 PK-15 and NSK cells. While swIFITM1a and 1b displayed prominent plasma-membrane
 148 localization, swIFITM 2 and 3 were found to co-localize with a marker for late endosomes. Over-
 149 expression of swIFITMs resulted in reduced influenza virus reporter activity and reduced viral
 150 titers. Although different expression levels of the swIFITMs make a direct comparison of the
 151 antiviral potencies difficult the data suggest that swIFITM2 and swIFITM3 display the strongest
 152 antiviral activity. Importantly, we also show that endogenous swIFITMs constitute a large part of
 153 the antiviral activity of IFN in porcine cells. In future studies, it will be interesting to characterize

154 the IFITMs from different swine breeds for their antiviral potential and thereby help to select pig
155 breeds with increased resistance to IAV infections.

156

157

158 **Acknowledgements**

159 This work was supported by grants from the Swiss National Science Foundation
160 (31003A_135278) and the Novartis Research Foundation to SSt. We would like to thank Prof.
161 Georg Kochs (University Hospital Freiburg, Germany) and Dr. Monika Engels (University of
162 Zurich, Switzerland) for providing porcine cell lines and swine influenza viruses and Prof. Wendy
163 Barclay (Imperial College London, UK) for the influenza virus reporter construct for porcine cells.
164 Imaging was performed with support of the Center for Microscopy and Image Analysis, University
165 of Zurich.

166 **References**

- 167 1. **Brass, A. L., I. C. Huang, Y. Benita, S. P. John, M. N. Krishnan, E. M. Feeley, B. J.**
168 **Ryan, J. L. Weyer, L. van der Weyden, E. Fikrig, D. J. Adams, R. J. Xavier, M.**
169 **Farzan, and S. J. Elledge.** 2009. The IFITM proteins mediate cellular resistance to
170 influenza A H1N1 virus, West Nile virus, and dengue virus. *Cell* **139**:1243-54.
- 171 2. **Mudhasani, R., J. P. Tran, C. Retterer, S. R. Radoshitzky, K. P. Kota, L. A. Altamura,**
172 **J. M. Smith, B. Z. Packard, J. H. Kuhn, J. Costantino, A. R. Garrison, C. S.**
173 **Schmaljohn, I. C. Huang, M. Farzan, and S. Bavari.** 2013. IFITM-2 and IFITM-3 but not
174 IFITM-1 restrict Rift Valley fever virus. *J Virol* **87**:8451-64.
- 175 3. **Huang, I. C., C. C. Bailey, J. L. Weyer, S. R. Radoshitzky, M. M. Becker, J. J. Chiang,**
176 **A. L. Brass, A. A. Ahmed, X. Chi, L. Dong, L. E. Longobardi, D. Boltz, J. H. Kuhn, S.**
177 **J. Elledge, S. Bavari, M. R. Denison, H. Choe, and M. Farzan.** 2011. Distinct patterns
178 of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.
179 *PLoS Pathog* **7**:e1001258.
- 180 4. **Anafu, A. A., C. H. Bowen, C. R. Chin, A. L. Brass, and G. H. Holm.** 2013. Interferon-
181 inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. *J Biol Chem*
182 **288**:17261-71.
- 183 5. **Lu, J., Q. Pan, L. Rong, W. He, S. L. Liu, and C. Liang.** 2011. The IFITM proteins
184 inhibit HIV-1 infection. *J Virol* **85**:2126-37.
- 185 6. **Everitt, A. R., S. Clare, T. Pertel, S. P. John, R. S. Wash, S. E. Smith, C. R. Chin, E.**
186 **M. Feeley, J. S. Sims, D. J. Adams, H. M. Wise, L. Kane, D. Goulding, P. Digard, V.**
187 **Anttila, J. K. Baillie, T. S. Walsh, D. A. Hume, A. Palotie, Y. Xue, V. Colonna, C.**
188 **Tyler-Smith, J. Dunning, S. B. Gordon, R. L. Smyth, P. J. Openshaw, G. Dougan, A.**
189 **L. Brass, and P. Kellam.** 2012. IFITM3 restricts the morbidity and mortality associated
190 with influenza. *Nature* **484**:519-23.
- 191 7. **Zhang, Y. H., Y. Zhao, N. Li, Y. C. Peng, E. Giannoulatou, R. H. Jin, H. P. Yan, H.**
192 **Wu, J. H. Liu, N. Liu, D. Y. Wang, Y. L. Shu, L. P. Ho, P. Kellam, A. McMichael, and**
193 **T. Dong.** 2013. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is
194 associated with severe influenza in Chinese individuals. *Nat Commun* **4**:1418.
- 195 8. **Feeley, E. M., J. S. Sims, S. P. John, C. R. Chin, T. Pertel, L. M. Chen, G. D. Gaiha,**
196 **B. J. Ryan, R. O. Donis, S. J. Elledge, and A. L. Brass.** 2011. IFITM3 inhibits influenza
197 A virus infection by preventing cytosolic entry. *PLoS Pathog* **7**:e1002337.
- 198 9. **Li, K., R. M. Markosyan, Y. M. Zheng, O. Golfetto, B. Bungart, M. Li, S. Ding, Y. He,**
199 **C. Liang, J. C. Lee, E. Gratton, F. S. Cohen, and S. L. Liu.** 2013. IFITM proteins
200 restrict viral membrane hemifusion. *PLoS Pathog* **9**:e1003124.
- 201 10. **Desai, T. M., M. Marin, C. R. Chin, G. Savidis, A. L. Brass, and G. B. Melikyan.** 2014.
202 IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following
203 virus-endosome hemifusion. *PLoS Pathog* **10**:e1004048.
- 204 11. **Amini-Bavil-Olyaei, S., Y. J. Choi, J. H. Lee, M. Shi, I. C. Huang, M. Farzan, and J.**
205 **U. Jung.** 2013. The antiviral effector IFITM3 disrupts intracellular cholesterol
206 homeostasis to block viral entry. *Cell Host Microbe* **13**:452-64.
- 207 12. **Yount, J. S., B. Moltedo, Y. Y. Yang, G. Charron, T. M. Moran, C. B. Lopez, and H. C.**
208 **Hang.** 2010. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity
209 of IFITM3. *Nat Chem Biol* **6**:610-4.
- 210 13. **John, S. P., C. R. Chin, J. M. Perreira, E. M. Feeley, A. M. Aker, G. Savidis, S. E.**
211 **Smith, A. E. Elia, A. R. Everitt, M. Vora, T. Pertel, S. J. Elledge, P. Kellam, and A. L.**
212 **Brass.** 2013. The CD225 domain of IFITM3 is required for both IFITM protein association
213 and inhibition of influenza A virus and dengue virus replication. *J Virol* **87**:7837-52.

- 214 14. **Yount, J. S., R. A. Karssemeijer, and H. C. Hang.** 2012. S-palmitoylation and
 215 ubiquitination differentially regulate interferon-induced transmembrane protein 3
 216 (IFITM3)-mediated resistance to influenza virus. *J Biol Chem* **287**:19631-41.
- 217 15. **Chesarino, N. M., T. M. McMichael, J. C. Hach, and J. S. Yount.** 2014.
 218 Phosphorylation of the Antiviral Protein IFITM3 Dually Regulates its Endocytosis and
 219 Ubiquitination. *J Biol Chem*.
- 220 16. **Jia, R., F. Xu, J. Qian, Y. Yao, C. Miao, Y. M. Zheng, S. L. Liu, F. Guo, Y. Geng, W.**
 221 **Qiao, and C. Liang.** 2014. Identification of an endocytic signal essential for the antiviral
 222 action of IFITM3. *Cell Microbiol*.
- 223 17. **Friedman, R. L., S. P. Manly, M. McMahon, I. M. Kerr, and G. R. Stark.** 1984.
 224 Transcriptional and posttranscriptional regulation of interferon-induced gene expression
 225 in human cells. *Cell* **38**:745-55.
- 226 18. **Miller, L. C., Z. Jiang, Y. Sang, G. P. Harhay, and K. M. Lager.** 2014. Evolutionary
 227 characterization of pig interferon-inducible transmembrane gene family and member
 228 expression dynamics in tracheobronchial lymph nodes of pigs infected with swine
 229 respiratory disease viruses. *Vet Immunol Immunopathol* **159**:180-91.
- 230 19. **Ferrari, M., A. Scalvini, M. N. Losio, A. Corradi, M. Soncini, E. Bignotti, E. Milanese,**
 231 **P. Ajmone-Marsan, S. Barlati, D. Bellotti, and M. Tonelli.** 2003. Establishment and
 232 characterization of two new pig cell lines for use in virological diagnostic laboratories. *J*
 233 *Virology Methods* **107**:205-12.
- 234 20. **Sun, E., J. He, and X. Zhuang.** 2012. Dissecting the role of COPI complexes on
 235 influenza virus infection. *J Virol*.
- 236 21. **Hoffmann, H. H., P. Palese, and M. L. Shaw.** 2008. Modulation of influenza virus
 237 replication by alteration of sodium ion transport and protein kinase C activity. *Antiviral*
 238 *Res* **80**:124-34.
- 239 22. **Moncorge, O., J. S. Long, A. V. Cauldwell, H. Zhou, S. J. Lycett, and W. S. Barclay.**
 240 2013. Investigation of influenza virus polymerase activity in pig cells. *J Virol* **87**:384-94.
- 241 23. **Neumann, G., and G. Hobom.** 1995. Mutational analysis of influenza virus promoter
 242 elements *in vivo*. *J.Gen.Virol.* **76**:1709-1717.
- 243
- 244

245 **Figure legends**

246 **Figure 1. Amino acid alignment of human, swine and chicken IFITM proteins and induction**

247 **of swine IFITMs upon IFN stimulation or virus infection. (A)** Amino acid alignment of human,

248 swine and chicken IFITM1, IFITM2, IFITM3 and IFITM5. Functional motifs and domains are

249 highlighted with colored boxes. Abbreviations: hu human, sw swine, ch chicken, TM

250 transmembrane domain **(B-D)** Induction of swIFITM expression by IFN or IAV infection. NSK **(B)**,

251 PK15 **(C)** or NpTr **(D)** porcine cells were infected with A/WSN/33 at an MOI of 0.01 or treated with

252 universal IFN (1000 U/ml) for 24h. At the indicated times post treatment, total mRNA was

253 extracted and used to perform RT-qPCR using specific oligos for the different swIFITMs or

254 swMX1 as positive control. Fold-changes were calculated according to the Pfaffl method using

255 swGAPDH mRNA as reference. A representative experiment from two biological replicates, each

256 performed in triplicate, is shown with error bars representing the 95% confidence interval.

257 Statistical significance between IFN-treated or IAV-infected cells and control untreated cells was

258 assessed by an unpaired two-tailed Student's t test (*, $P < 0.05$). **(E)** NpTr cells were transfected

259 with poly(I:C) or infected with A/PR/8/34 Δ NS1 (Δ NS1) or Sendavirus (SeV) for 24h. Total mRNA

260 was extracted and used to perform RT-qPCR using specific oligos. Fold-changes were calculated

261 according to the Pfaffl method using swGAPDH mRNA as reference. A representative experiment

262 is shown with error bars representing the 95% confidence interval. Statistical significance

263 between poly(I:C)-treated or infected cells and control untreated cells was assessed by an

264 unpaired two-tailed Student's t test (*, $P < 0.05$). **(F)** IAV replication in porcine cell lines. NSK, PK-

265 15 and NpTr cells were infected with A/WSN/33 as described in B-D and viral titers in the

266 supernatant at 24/48h p.i. were determined by plaque assay. The dashed line indicates the limit

267 of detection.

268 **Figure 2. Localization of human and swine IFITM proteins in human and porcine cells. (A)**

269 Representative confocal images of human A549 **(a-g)**, porcine NpTr cells **(h-k)** or porcine NSK

cells (**I-o**) transfected with flag-tagged human or porcine IFITM-encoding constructs are shown. IFITMs were stained using an antibody against the flag-epitope (red), late endosomes using an antibody against the late endosomal marker LBPA (green) and cell nuclei were marked using DAPI (blue). Cells were imaged using a 63x objective and a magnification of 3x (scale bar = 10 μ m) (**B**) Co-localization of IFITM proteins with the late endosome marker LBPA was quantified. Horizontal bars represent the mean of the Pearson's correlation coefficient (Rr) calculated for 8-12 cells using ImageJ, with error bars marking the 95% confidence interval. Statistical significance of increased co-localization for the indicated IFITM construct compared to huIFITM1 or swIFITM1a, respectively, was assessed by an unpaired two-tailed Student's t test (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$). (**C**) Representative confocal images of NSK cells transfected with flag-tagged porcine IFITM-encoding constructs and infected with A/WSN/33 at an MOI of 5 are shown. IFITMs were stained using an antibody against the flag-epitope (red), infection was controlled using an antibody against IAV NP (green) and cell nuclei were marked using DAPI (blue). Cells were imaged using a 63x objective and a magnification of 3x (scale bar = 10 μ m).


Figure 3. Expression of swIFITMs potently inhibits IAV. (A-B) Transient transfection assays. HEK293-T (**A**) and NpTr (**B**) cells were transfected with an IAV-dependent firefly luciferase reporter construct and increasing amounts of plasmids encoding flag-tagged swine IFITMs. At 24h post transfection, cells were infected with A/WSN/33 at an MOI of 0.1 (**A**) or 1 (**B**). At 24h p.i., cells were lysed and firefly luciferase activity measured. Data were normalized to luciferase activity in cells transfected with an inactive Mx1 mutant (neg con), while murine Mx1 and human IFITM3 served as positive controls (pos con). Mean values from three biological replicates, each performed in triplicate, are shown with error bars representing standard deviation. Statistical significance between cells transfected with swIFITMs and cells expressing the negative control was assessed by an unpaired two-tailed Student's t test (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$). Expression levels of swine IFITM proteins were confirmed

296 by western blot, quantified using Multi Gauge software and expression levels in relation to human
 297 IFITM3 expression are given below the western blots. **(C-H) Stable cell lines expressing**
 298 **swIFITMs.** NpTr **(C, D)** or NSK **(F, G)** cells stably overexpressing flag-tagged swIFITM proteins
 299 were infected with A/HongKong/68 (MOI 1) **(C, F)** or A/swine/Zurich/25/06 (MOI 1) **(D, G)**. At 48h
 300 p.i., supernatants were harvested and virus titers determined via plaque assay on MDCK cells.
 301 Mean values from three replicates are shown with error bars representing standard deviation.
 302 Statistical significance between titers from cells expressing swIFITM proteins and cells
 303 transduced with the empty vector (con) was assessed by an unpaired two-tailed Student's t test
 304 (*, $P<0.05$; **, $P<0.01$; ***, $P<0.001$; ****, $P<0.0001$). The dashed lines indicate the limit of
 305 detection. Expression levels of swIFITMs were confirmed by western blot, quantified by Multi
 306 Gauge software and expression levels relative to the strongest band are given below the western
 307 blots **(E, H)**.


308 **Figure 4. Endogenous swIFITMs contribute to the antiviral activity of IFN in porcine cells.**
 309 **(A)** NSK cells were transfected with two siRNAs targeting swIFITMs (#1 and #2) or the viral
 310 nucleoprotein (NP) or a non-targeting control siRNA. At 36h post transfection, cells were either
 311 left untreated or treated with universal type I IFN (1000 U/ml). At 12h post treatment, cells were
 312 infected with A/WSN/33 (MOI 0.0001) and supernatants were harvested at 24h p.i. Viral titers
 313 were determined by plaque assay. Mean values with standard deviation from three replicates are
 314 shown. The dashed line indicates the limit of detection. **(B, C)** A parallel set of samples was
 315 siRNA-transfected and mock or interferon-treated as above. At 48h post transfection, cells were
 316 harvested and mRNA levels of the different swIFITMs and swMX1 were determined by RT-qPCR.
 317 Fold-changes were calculated according to the Pfaffl method using swGAPDH mRNA as
 318 reference. Mean values with the 95% confidence interval from three replicates are shown.
 319 Statistical significance between NP- or swIFITM-silenced cells and cells transfected with the non-
 320 targeting siRNA was assessed by an unpaired two-tailed Student's t test (*, $P<0.05$). **(D)** Stable
 321 NSK cells expressing swIFITMs were transfected with either an siRNA targeting swIFITMs or a

322 non-targeting control siRNA (con). At 48h post transfection cells were lyzed and the amount of
 323 flag-tagged swIFITMs assessed by western blot. Results for two different swIFITM-specific
 324 siRNAs (#1 and #2) are shown. **(E)** NSK cells were transfected with either an siRNA targeting
 325 IAV NP or a non-targeting control siRNA (con) . At 36h post transfection cells were treated with
 326 universal type I IFN (1000 U/ml) and 12h post treatment cells were infected with A/WSN/33 (MOI
 327 0.0001) as in 4A. At 24h p.i. cells were lyzed and NP levels assessed by western blot.


A




B




C




D





E




F









A




B



C



D



E

